Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial.
Benoit Samson
No relevant relationships to disclose
Christophe Tournigand
Honoraria - Roche
Werner Scheithauer
No relevant relationships to disclose
Gérard Lledo
No relevant relationships to disclose
Frédéric Viret
No relevant relationships to disclose
Thierry André
Honoraria - Roche
Jean François Ramée
No relevant relationships to disclose
Nicole Tubiana-Mathieu
No relevant relationships to disclose
Jérôme Dauba
No relevant relationships to disclose
Olivier Dupuis
No relevant relationships to disclose
Yves Rinaldi
No relevant relationships to disclose
May Mabro
No relevant relationships to disclose
Nathalie Aucoin
No relevant relationships to disclose
Ahmed Khalil
No relevant relationships to disclose
Jean Latreille
No relevant relationships to disclose
Christophe Louvet
No relevant relationships to disclose
David Brusquant
No relevant relationships to disclose
Franck Bonnetain
No relevant relationships to disclose
Benoist Chibaudel
No relevant relationships to disclose
Aimery De Gramont
Honoraria - Roche